COO

Business profile & competitive position

The Cooper Companies, Inc. operates in the Healthcare sector, specifically the Medical - Instruments & Supplies industry. It is a global medical device company headquartered in San Ramon, California, organized around two distinct segments. CooperVision develops, manufactures, and markets single-use, two-week, and monthly contact lenses along with specialty eyecare products such as silicone hydrogel lenses, orthokeratology lenses, scleral lenses, and the MiSight 1 day myopia-management lens. CooperSurgical offers more than 600 products and services focused on fertility and women's health, including medical devices for gynecology, obstetrics, contraception, and labor and delivery, as well as cord blood and tissue storage, IVF support, donor gametes, cryopreservation, and genomic services.

The company reports that its products reach more than 130 countries and positively impact over 50 million lives each year. Its R&D workforce totals approximately 500 people across both segments. A notable differentiator is that MiSight 1 day is the only contact lens approved by the FDA, the Chinese NMPA, and the Japanese MHLW to both slow the progression of and correct myopia in age-appropriate children.

What do the margin and return figures imply about moat? The 13.5% net margin is respectable, indicating that Cooper can price above its manufacturing and operating costs, which is consistent with a mix of specialty medical devices and recurring consumables like contact lenses. But the 6.9% ROE is modest; returns on equity in the high-single-digit range generally do not point to a capital-light fortress. That figure is consistent with an acquisitive medical-device operator—investing in distribution, packaging, and strategic transactions such as those highlighted for CooperSurgical—where goodwill and equity base can dampen return metrics. In other words, the numbers say Cooper is a profitable, diversified device company with meaningful regulatory reach, but not one that converts equity into extraordinary returns.

Financial posture

Cooper carries an $11.0 billion market capitalization and trades at a P/E of 19.3. Its net margin is 13.5%, ROE is 6.9%, and beta is 0.82. At the time of this snapshot, the stock price stood at $56.49, with an RSI of 36.6 and a 50-day EMA of $63.23.

A beta of 0.82 indicates lower systemic volatility than the overall market, which is typical for a healthcare consumables and devices business with recurring revenue streams such as contact lens replacements. The P/E of 19.3 sits in a moderate range for the Medical - Instruments & Supplies group, neither deeply discounted nor aggressively valued relative to broader healthcare norms. The 13.5% net margin supports that valuation by showing the company retains a healthy slice of revenue after all costs. However, the 6.9% ROE raises a capital-efficiency question: if Cooper is spending heavily on acquisitions, distribution expansion, and segment integration, the payoff may be showing up in revenue and market footprint more than in equity returns.

Technically, the current RSI of 36.6 is approaching traditional oversold territory and the price sits below the $63.23 50-day EMA, suggesting recent selling pressure. Taken together, Cooper looks like a lower-volatility, profitable healthcare name that is currently under near-term price pressure even though its trailing fundamentals remain intact.

Strategic priorities & outlook

According to the company's most recent 10-K filing, CooperVision's near-term priorities center on three things. First, it is focused on greater worldwide market penetration of recently introduced products and on expanding its presence in existing and emerging markets. Second, it is increasing investment in distribution and packaging capabilities to support business growth and quality service. Third, it is investing to build the myopia-management market by educating eye-care practitioners, patients, and their families.

On the CooperSurgical side, management expects to continue investing in the business, including through strategic transactions, to expand its integrated solutions model within fertility and women's health.

These priorities line up with the financial posture described above. The emphasis on distribution, packaging, and market development explains why capital is being deployed ahead of return acceleration, while the strategy of using strategic transactions to broaden CooperSurgical's integrated offering explains why the balance sheet has likely absorbed deal-related equity and goodwill. The myopia-management push, anchored by MiSight 1 day's regulatory status in the U.S., China, and Japan, is the clearest organic growth engine with limited direct competition in the pediatric myopia segment.

Macro & geopolitical exposure

As a Medical - Instruments & Supplies company with global distribution, Cooper is exposed to several macro and geopolitical forces that are inherent to the industry rather than unique to the firm.

Regulatory clearance is a core risk. The FDA, Chinese NMPA, and Japanese MHLW approvals cited for MiSight illustrate how gatekeeper agencies in major markets directly shape product launch timelines and revenue potential. Tariffs and trade policy also matter; medical devices and their raw-material supply chains cross borders routinely, so any escalation in duties between the U.S. and Asia or Europe can affect input costs and end-product pricing. Currency risk is present because more than 130 countries contribute to sales, meaning a stronger U.S. dollar mechanically pressures reported revenue and margin.

Commodity inputs—specialty polymers, plastics, and packaging materials—can move with oil prices and petrochemical costs, which affects lens manufacturing economics. More broadly, healthcare reimbursement and insurance-coverage trends influence CooperSurgical's fertility and women's health revenue, while demographic shifts such as rising myopia rates support CooperVision's myopia-management market. Finally, litigation and securities-law scrutiny are recurring features of the healthcare device landscape and can create headline risk independent of operational performance.

Recent developments

Recent news has centered on a cluster of law-firm investigations rather than operational updates. On October 2, 2026, GlobeNewswire reported that the Law Offices of Frank R. Cruz continued a securities fraud investigation and urged shareholders who lost money to contact the firm. On October 3, 2026, Newsfile Corp. published a ROSEN notice encouraging Cooper investors to inquire about a securities class-action investigation. Another ROSEN release, again via Newsfile Corp., followed on October 4, 2026. On October 5, 2026, GlobeNewswire carried a Law Offices of Howard G. Smith release asking Cooper shareholders who lost money to contact the firm regarding a securities fraud investigation.

It is important to treat these as plaintiff-firm announcements and allegations, not adjudicated findings or settled facts. The four-day concentration, however, has created headline risk around the stock. That risk appears to overlap with the recent technical weakness: the share price is at $56.49, below its 50-day EMA of $63.23, with an RSI of 36.6. Traders and long-term holders alike should view these items as disclosure and governance risk factors that could affect volatility until more facts emerge or any formal proceedings are resolved.

Earnings behavior & post-earnings drift

Cooper's earnings track record against analyst estimates is striking: over the last eight reported quarters, it beat consensus EPS every time, for a 100% beat rate, with an average earnings surprise of 4.2%. Yet the average five-day price move after earnings across those same quarters was -2.34%, classified as a "down" drift direction.

This is the classic "beat does not equal bounce" pattern. The most recent four quarters illustrate the disconnect clearly. On September 9, 2026, Cooper reported EPS of $1.15 versus a $1.12 estimate, a 2.7% positive surprise, but the stock fell 14.67% the next day and 13.97% over the following five days. On June 4, 2026, EPS of $1.21 beat the $1.10 estimate by 10.0%, and the stock rose 8.58% the next day and 8.85% over the next five sessions. On March 5, 2026, EPS of $1.10 beat the $1.03 estimate by 6.8%, yet the stock dropped 4.55% the next day and 10.82% over five days. On December 4, 2025, EPS of $1.15 beat the $1.11 estimate by 3.6%, producing a 5.67% next-day gain and a 6.59% five-day gain.

Two of the last four beats were met with sharp post-earnings selling, including the most recent quarter. The 100% beat rate combined with the -2.34% average drift suggests the market's real expectation is being set by factors beyond the headline EPS number—likely guidance, commentary around CooperSurgical integration, myopia-market traction, or margin trajectory. With the next scheduled earnings release on December 3, 2026 (after the close) and the consensus EPS estimate at $1.07, readers should be cautious about assuming that another beat, if it occurs, will automatically extend upward.

For a deeper dive into how institutional analysts, quant models, and broader market positioning are currently viewing Cooper beyond these headline figures, it is worth examining the full institutional verdict on the name.